# Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide

> **NCT02957864** · PHASE4 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 80 (estimated)

## Conditions studied

- Renal Insufficiency,Chronic
- Hiv
- Therapeutic Agent Toxicity

## Interventions

- **DRUG:** tenofovir alafenamide
- **DRUG:** abacavir

## Key facts

- **NCT ID:** NCT02957864
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2020-06
- **Final completion:** 2020-09
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02957864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02957864, "Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02957864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*